Treatments
553 articles
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
Research Updates from ASCO GI 2023
Read the latest clinical trial and research updates from the 2023 ASCO GI meeting, including a review of genetic testing uptake.
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.
A Year in Review: 2020
In March 2020, life as we knew it changed. The way we work, the way we gather, the way we each live our daily lives all felt upended, seemingly overnight. The global pandemic of COVID-19 affected everything, including cancer care and research. COVID-19 brought new risks to cancer patients, whose immune systems are compromised from […]
Progress and Promise—Research in 2023
What advances were made in 2023 for pancreatic cancer treatments? Where is research headed in the coming year?
AACR Special Conference Highlights Advances in Pancreatic Cancer Research
Here are some of the most interesting highlights from the 2024 AACR Special Conference on Pancreatic Cancer Research.
Pancreatic Cancer Research Updates from ASCO 2024
Learn about the latest developments in pancreatic cancer research into immunotherapy and chemotherapy from the ASCO 2024 meeting.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Advances in Pancreatic Neuroendocrine Tumor (PNET) Treatments
Dr. Diane Reidy-Lagunes outlines the current state of treatments for pancreatic neuroendocrine tumors (PNETs).
Pancreatic Cancer Science—2021 in Review
As the year winds down Let’s Win provides an overall look at the highlights of 2021 in pancreatic cancer science.
Research Highlights from ASCO GI 2026
The latest research on drugs targeting KRAS and new immuotherapy combinations were among the highlights of ASCO GI 2026.
PASS-01 Trial Results: Filling the Gaps in Personalized Medicine
The PASS-01 trial results provide data to help clarify how the subtypes of pancreatic cancer respond to the two main treatment protocols.
Research and Other Highlights from the 2023 AACR Annual Meeting
The 2023 AACR meeting focused on the latest research into KRAS, other immunotherapy approaches, and honored Dr. Elizabeth Jaffee.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
Putting the Immune System on the Offensive
A discussion of immunology in cancer treatment, focusing on the work of Elizabeth Jaffe, M.D., and her cancer vaccine and checkpoint inhibitors.